New drug shows promise for lupus in asian patients

NCT ID NCT04931563

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called anifrolumab in 277 Asian adults with active lupus. The goal was to see if it could better control the disease compared to a placebo, when added to standard treatments. Participants received the drug or placebo through an IV, and researchers measured how many had less disease activity after one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

277 people

The number who actually took part.

Started

Sep 2021

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key inclusion criteria: 1. Aged 18 to 70 years. 2. Body weight ≥ 40 kg. 3. Confirmed diagnosis of SLE(1997 ACR revised criteria) for ≥ 24 weeks. 4. Must be receiving at least one of the following SOC regimens at screening: 1. oral prednisone monotherapy: ≥ 7.5 mg/day and ≤ 40 mg/day, stable for \> 2 weeks; 2. Immunosuppressant(s) with or without OCS and must be stable for ≥ 8 weeks; 3. Oral prednisone plus immunosuppressant: start date, stability and maximum dose required. 5. At least one of these antibodies positive: ANA, anti-dsDNA and anti-Smith. 6. SLEDAI-2K score ≥ 6 points at screening and "Clinical" SLEDAI-2K score ≥4 points at both screening and Day1(randomisation), and BILAG with at least 1 level A organ system or 2 level B organ system, and PGA score ≥ 1.0 at screening. 7. Chest imaging shows no clinically significant abnormalities (unless due to SLE). 8. No evidence or medical history of active TB, indeterminate TB should be referred to a TB specialist. 9. All participants should use effective contraception methods as protocol requests. 10. Any negative SARS-CoV-2 RT-PCR test result at screening and no known or suspected COVID-19 infection or exposure within 2 weeks prior to screening and between screening and randomisation visits. Key exclusion criteria: 1. History or current diagnose of clinically significant non-SLE related vasculitis, severe or unstable neuropsychiatric SLE, active severe SLE-driven renal disease, catastrophic anti-phospholipid syndrome, inflammatory joint or skin disease other than SLE, non-SLE disease that has required treatment of certain dosage of corticosteroid. 2. History or evidence of suicidal ideation or suicidal behavior. 3. History or current diagnose of MTCD or overlap syndrome, unless overlap with RA or MTCD which has developed into SLE. 4. History of recurrent infection requiring hospitalization and IV antibiotics, or opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of randomization, or clinically significant chronic infection within 3 months, or recent infection still under treatment. 5. History of immunodeficient condition, HIV positive included. 6. Confirmed HBsAg positive, or HBcAb positive and HBV DNA detectable, or hepatitis C antibody positive. 7. History of severe case of herpes zoster. 8. Herpes zoster, CMV or EB infection which has not completely resolved within 12 weeks before screening. 9. Acute COVID-19 infection or history of severe COVID-19. 10. History of cancer, apart from cured squamous or basal cell carcinoma and cervical cancer in situ. 11. Female participants with abnormal pap smear results. 12. Prior receipt of anifrolumab ,or any commercially available Janus kinase (JAK) inhibitor ≤ 12 weeks or Bruton's tyrosine kinase (BTK) inhibitor ≤ 24weeks prior to signing the ICF; any investigational medicinal product(small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater. 13. Known history of allergy to any component of the IP formulation or protein related products. 14. Receipt of any of the following: 1. Intramuscular or IV glucocorticosteroids within 6 weeks; 2. Any live or attenuated vaccine within 8 weeks; 3. Any restricted medication listed in protocol; 4. Blood transfusion within 4 weeks. 15 Regular use of \> 1 NSAID within 2 weeks or receipt of fluctuating doses of a NSAID within 2 weeks. 16\. Certain laboratory test results requirements. 17. Concurrent enrolment in another clinical study. 18. History or current alcohol, drug or chemical abuse within 1 year. 19. Major surgery within 8 weeks or planned elective major surgery.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Active systemic lupus erythematosus

Contacts and locations

Locations

Research Site

Baoding, 071000, China
Research Site

Baotou, 014010, China
Research Site

Beijing, 100029, China
Research Site

Beijing, 100034, China
Research Site

Beijing, 100144, China
Research Site

Beijing, 100191, China
Research Site

Beijing, 100730, China
Research Site

Bengbu, 233004, China
Research Site

Binzhou, 256603, China
Research Site

Changchun, China
Research Site

Changsha, 410008, China
Research Site

Chuangchun, 130012, China
Research Site

Guangzhou, 510080, China
Research Site

Guangzhou, 510260, China
Research Site

Guilin, 541001, China
Research Site

Hangzhou, 310006, China
Research Site

Hengyang, 421001, China
Research Site

Jieyang, 522000, China
Research Site

Jinan, 250012, China
Research Site

Jining, 272011, China
Research Site

Kunming, 650032, China
Research Site

Lanzhou, 730000, China
Research Site

Linyi, 276003, China
Research Site

Luoyang, 471003, China
Research Site

Nanchang, 330006, China
Research Site

Nanchong, 637000, China
Research Site

Nanjing, 210008, China
Research Site

Nanyang, 473005, China
Research Site

Shanghai, 200025, China
Research Site

Shengyang, 110004, China
Research Site

Shenyang, 110001, China
Research Site

Shenzhen, 518020, China
Research Site

Shijiazhuang, 050001, China
Research Site

Suzhou, 215006, China
Research Site

Tianjin, 300050, China
Research Site

Ürümqi, 831118, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430030, China
Research Site

Wuxi, 214002, China
Research Site

Xiamen, 361003, China
Research Site

Xinxiang, 453002, China
Research Site

Yinchuan, 750004, China
Research Site

Zaozhuang, 277102, China
Research Site

Zhengzhou, 450052, China
Research Site

Hong Kong, 00000, Hong Kong
Research Site

Hong Kong, Hong Kong
Research Site

Davao City, PH-8000, Philippines
Research Site

Iloilo City, 5000, Philippines
Research Site

Lipa City, 4217, Philippines
Research Site

Manila, 1000, Philippines
Research Site

Quezon City, 1112, Philippines
Research Site

Gwangju, 501-757, South Korea
Research Site

Seoul, 04763, South Korea
Research Site

Seoul, 6591, South Korea
Research Site

Suwon, 16499, South Korea
Research Site

Kaohsiung City, 81362, Taiwan
Research Site

New Taipei City, 220, Taiwan
Research Site

New Taipei City, 23561, Taiwan
Research Site

Taichung, 40447, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Taipei, 11220, Taiwan
Research Site

Taipei, 114, Taiwan
Research Site

Taoyuan, 333, Taiwan
Research Site

Bangkok, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.

New lupus drug candidate D-2570 enters Mid-Stage trial